To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
32 Current news about the topic neuropathic pain
rss
Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
27-01-2012
Affectis Pharmaceuticals AG announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis.The European patent EP2105164 is related to the ...
ExonHit Extends Strategic Collaboration with Allergan
Agreement to extend the collaboration until December 2013
08-11-2011
ExonHit S.A. y announced the extension of its existing drug discovery collaboration with Allergan Sales, LLC. The collaboration was initiated in December 2002, and extended several times. It now is further extended until December 2013. The collaboration will continue to focus on the ...
Marijuana component could ease pain from chemotherapy drugs
10-10-2011
A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.The researchers published their findings, "Cannabidiol Prevents ...
Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia
20-09-2011
Spinifex Pharmaceuticals, an Australian pain drug development company, announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where ...
Evotec receives Milestone as Boehringer Ingelheim starts Phase I clinical trial in Pain
03-06-2011
Evotec AG announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million. The compound, which was discovered and optimised within the alliance, is being developed as a ...
Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta
30-11-2010
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride ...
Galapagos and University of Bristol enter drug discovery collaboration in chronic pain
20-07-2010
Galapagos NV and the University of Bristol announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). Galapagos' service division BioFocus will provide hit-to-lead and lead optimization services for a ...
Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
Evotec receives EUR 2.0 million milestone payment from Boehringer Ingelheim
20-05-2010
Evotec AG announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million. The compound, which was discovered and ...
Ablynx Successfully Generates Nanobodies Against an Ion Channel and Announces New GPCR Programme
13-01-2010
Ablynx announced two significant advances achieved within its R&D portfolio. In the first, it has demonstrated the successful generation of functional Nanobodies against an ion channel. In the second, Ablynx has demonstrated in vivo proof-of-concept for a GPCR targeting stem cell mobilization ...
Addex' ADX10059 has potential for Parkinson's disease levodopa induced dyskinesia (PD-LID)
15-09-2009
Addex Pharmaceuticals reported that its lead product, ADX10059, which is nearing completion of Phase IIb testing in gastroesophageal reflux disease (GERD) and migraine prevention, also has demonstrated significant potential in a non-human primate model of Parkinson's disease levodopa induced ...
Netmeeting
